|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Teoh D and Secord AA: Antiangiogenic
agents in combination with chemotherapy for the treatment of
epithelial ovarian cancer. Int J Gynecol Cancer. 22:348–359. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Usha L, Sill MW, Darcy KM, et al: A
Gynecologic Oncology Group phase II trial of the protein kinase
C-beta inhibitor, enzastaurin and evaluation of markers with
potential predictive and prognostic value in persistent or
recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecol Oncol. 121:455–461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu H, Yao L, Mei J and Li F: Development
of synthetic of peptide-functionalized liposome for enhanced
targeted ovarian carcinoma therapy. Int J Clin Exp Pathol.
8:207–216. 2015.PubMed/NCBI
|
|
5
|
Kannan K, Coarfa C, Chao PW, et al:
Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated
AKT2 fusion kinase in high-grade serous ovarian carcinoma. Proc
Natl Acad Sci USA. Mar 2–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gurler H, Yu Y, Choi J, Kajdacsy-Balla AA
and Barbolina MV: Three-dimensional collagen type I matrix
up-regulates nuclear isoforms of the microtubule associated protein
tau implicated in resistance to Paclitaxel therapy in ovarian
carcinoma. Int J Mol Sci. 16:3419–3433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morris LG, Veeriah S and Chan TA: Genetic
determinants at the interface of cancer and neurodegenerative
disease. Oncogene. 29:3453–3464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao L, Liu X, Lin EJ, et al: Environmental
and genetic activation of a brain-adipocyte BDNF/leptin axis causes
cancer remission and inhibition. Cell. 142:52–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chilton JK: Molecular mechanisms of axon
guidance. Dev Biol. 292:13–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dickson BJ: Molecular mechanisms of axon
guidance. Science. 298:1959–1964. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bielenberg DR, Hida Y, Shimizu A, et al:
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a
poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J
Clin Invest. 114:1260–1271. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Christensen C, Ambartsumian N, Gilestro G,
et al: Proteolytic processing converts the repelling signal Sema3E
into an inducer of invasive growth and lung metastasis. Cancer Res.
65:6167–6177. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neufeld G and Kessler O: The semaphorins:
versatile regulators of tumour progression and tumour angiogenesis.
Nat Rev Cancer. 8:632–645. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kigel B, Varshavsky A, Kessler O and
Neufeld G: Successful inhibition of tumor development by specific
class-3 semaphorins is associated with expression of appropriate
semaphorin receptors by tumor cells. PLoS One. 3:e32872008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kessler O, Shraga-Heled N, Lange T, et al:
Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res.
64:1008–1015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Casazza A, Fu X, Johansson I, et al:
Systemic and targeted delivery of semaphorin 3A inhibits tumor
angiogenesis and progression in mouse tumor models. Arterioscler
Thromb Vasc Biol. 31:741–749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maione F, Molla F, Meda C, et al:
Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks
tumor growth and normalizes tumor vasculature in transgenic mouse
models. J Clin Invest. 119:3356–3372. 2009.PubMed/NCBI
|
|
18
|
Sakurai A, Gavard J, Annas-Linhares Y, et
al: Semaphorin 3E initiates antiangiogenic signaling through plexin
D1 by regulating Arf6 and R-Ras. Mol Cell Biol. 30:3086–3098. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Varshavsky A, Kessler O, Abramovitch S, et
al: Semaphorin-3B is an angiogenesis inhibitor that is inactivated
by furin-like pro-protein convertases. Cancer Res. 68:6922–6931.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rolny C, Capparuccia L, Casazza A, et al:
The tumor suppressor semaphorin 3B triggers a prometastatic program
mediated by interleukin 8 and the tumor microenvironment. J Exp
Med. 205:1155–1171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng C, Zhou Q, Wu F, et al: Semaphorin3F
down-regulates the expression of integrin alpha(v)beta3 and
sensitizes multicellular tumor spheroids to chemotherapy via the
neuropilin-2 receptor in vitro. Chemotherapy. 55:344–352. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bagci T, Wu JK, Pfannl R, Ilag LL and Jay
DG: Autocrine semaphorin 3A signaling promotes glioblastoma
dispersal. Oncogene. 28:3537–3550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li K, Chen MK, Li LY, et al: The
predictive value of sema-phorins 3 expression in biopsies for
biochemical recurrence of patients with low- and intermediate-risk
prostate cancer. Neoplasma. 60:683–689. 2013. View Article : Google Scholar
|
|
24
|
Staton CA, Shaw LA, Valluru M, et al:
Expression of class 3 semaphorins and their receptors in human
breast neoplasia. Histopathology. 59:274–282. 2011.PubMed/NCBI
|
|
25
|
Neufeld G, Shraga-Heled N, Lange T,
Guttmann-Raviv N, Herzog Y and Kessler O: Semaphorins in cancer.
Front Biosci. 10:751–760. 2005. View
Article : Google Scholar
|
|
26
|
Goshima Y, Ito T, Sasaki Y and Nakamura F:
Semaphorins as signals for cell repulsion and invasion. J Clin
Invest. 109:993–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tomizawa Y, Sekido Y, Kondo M, et al:
Inhibition of lung cancer cell growth and induction of apoptosis
after reexpression of 3p21.3 candidate tumor suppressor gene
SEMA3B. Proc Natl Acad Sci USA. 98:13954–13959. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xiang R, Davalos AR, Hensel CH, Zhou XJ,
Tse C and Naylor SL: Semaphorin 3F gene from human 3p21.3
suppresses tumor formation in nude mice. Cancer Res. 62:2637–2643.
2002.PubMed/NCBI
|
|
29
|
Vacca A, Scavelli C, Serini G, et al: Loss
of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow
endothelial cells of patients with multiple myeloma. Blood.
108:1661–1667. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moriya J, Minamino T, Tateno K, et al:
Inhibition of semaphorin as a novel strategy for therapeutic
angiogenesis. Circ Res. 106:391–398. 2010. View Article : Google Scholar
|
|
31
|
Pan H, Wanami LS, Dissanayake TR and
Bachelder RE: Autocrine semaphorin3A stimulates alpha2 beta1
integrin expression/function in breast tumor cells. Breast Cancer
Res Treat. 118:197–205. 2009. View Article : Google Scholar
|
|
32
|
Herman JG and Meadows GG: Increased class
3 semaphorin expression modulates the invasive and adhesive
properties of prostate cancer cells. Int J Oncol. 30:1231–1238.
2007.PubMed/NCBI
|
|
33
|
Catalano A, Caprari P, Rodilossi S, et al:
Cross-talk between vascular endothelial growth factor and
semaphorin-3A pathway in the regulation of normal and malignant
mesothelial cell proliferation. FASEB J. 18:358–360. 2004.
|
|
34
|
Oinuma I, Ishikawa Y, Katoh H and Negishi
M: The Semaphorin 4D receptor Plexin-B1 is a GTPase activating
protein for R-Ras. Science. 305:862–865. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toyofuku T, Yoshida J, Sugimoto T, et al:
FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat
Neurosci. 8:1712–1719. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gaziel-Sovran A, Segura MF, Di Micco R, et
al: miR-30b/30d regulation of GalNAc transferases enhances invasion
and immunosuppression during metastasis. Cancer Cell. 20:104–118.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dubois L, Andersson K, Asplund A and
Bjorkelund H: Evaluating real-time immunohistochemistry on multiple
tissue samples, multiple targets and multiple antibody labeling
methods. BMC Res Notes. 6:5422013. View Article : Google Scholar : PubMed/NCBI
|
